Strategic drug discovery collaboration (2015) with Pfizer to research and develop potential new medicines directed at up to 10 GPCR targets across multiple therapeutic areas.

We will use our proprietary GPCR structure-guided platform to help deliver stabilized GPCRs (StaR® proteins), high-resolution crystal structures and other technologies to support the discovery of potential novel agents directed to the GPCR targets selected by Pfizer. Pfizer will be responsible for developing and commercializing any potential therapeutic agents (small molecules or biologics derived from StaR® antigens) for each target and will have exclusive global rights to any potential resulting agents.

We are eligible to receive R&D, regulatory and commercial milestone payments of up to $189 million per target and potential tiered royalties on the net sales of any products that are commercialized by Pfizer. In addition, Pfizer made a $33 million investment in Sosei Group Corporation.